Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 25 mg - 25 EUR
  • 100 mg - 75 EUR
  • 250 mg - 150 EUR

Imatinib mesylate

Imatinib is an inhibitor of several tyrosine kinases that is selective for the oncoproteins BCR/Abl, c-Kit and PDGFR. It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and some other diseases in which these kinases are strongly expressed or unusually active. As one of the first cancer drugs developed using the principles of rational drug design based on an understanding of how cancer cells work, Imatinib is a ground-breaking compound. It was approved in the U.S. in 2001 for the treatment of Philadelphia-chromosome positive (Ph+) CML and in 2002 for the treatment of patients with KIT (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).

catalogue number: I040
synonyms: Gleevec, Glivec, STI571
CAS: 220127-57-1
MW: 589.7 g/mol

References
Nat Rev Drug Discov. 2002 Jul;1(7):493-502. PMID: 12120256